SUMMIT THERAPEUTICS INC. (SMMT)
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
📈 **POSITIVE** • High confidence analysis (90%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business